RegenX LLC

Biotech · Public

Injectable collagen-based therapeutic using CRISPR-engineered human fibroblasts to accelerate tendon and ligament repair

Grants
$256K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: An Injectable Treatment for the Repair of Damaged Tendons and Ligaments$255,947
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2685Eyebiotech Ltd—$486
2686RevOpsis Holdings LLC—$1
2687ARTIAM BIO INC.——
2688RegenX LLC——
2689THINK BIOSCIENCE, INC.——
2690LAB11 THERAPEUTICS INC.——
2691SD NANOSCIENCES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.